MediPharm Labs Corp.

TSX:LABS Stock Report

Market Cap: CA$29.9m

MediPharm Labs Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for MediPharm Labs.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Pharmaceuticals earnings growth13.6%
Revenue growth raten/a
Future return on equityn/a
Analyst coverage

None

Last updatedn/a

Recent future growth updates

Recent updates

Analysis Article • Aug 14

MediPharm Labs Corp. (TSE:LABS) Stock Rockets 29% As Investors Are Less Pessimistic Than Expected

TSX:LABS 1 Year Share Price vs Fair Value Explore MediPharm Labs's Fair Values from the Community and select yours...
Analysis Article • Mar 26

MediPharm Labs Corp.'s (TSE:LABS) Shares Leap 54% Yet They're Still Not Telling The Full Story

MediPharm Labs Corp. ( TSE:LABS ) shareholders have had their patience rewarded with a 54% share price jump in the last...
Analysis Article • Oct 11

MediPharm Labs Corp. (TSE:LABS) Doing What It Can To Lift Shares

There wouldn't be many who think MediPharm Labs Corp.'s ( TSE:LABS ) price-to-sales (or "P/S") ratio of 0.8x is worth a...
Analysis Article • May 29

MediPharm Labs (TSE:LABS) Is Using Debt Safely

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Analysis Article • Mar 23

Market Might Still Lack Some Conviction On MediPharm Labs Corp. (TSE:LABS) Even After 31% Share Price Boost

Despite an already strong run, MediPharm Labs Corp. ( TSE:LABS ) shares have been powering on, with a gain of 31% in...
Analysis Article • Jan 10

Does MediPharm Labs (TSE:LABS) Have A Healthy Balance Sheet?

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Analysis Article • Sep 06

MediPharm Labs (TSE:LABS) Has Debt But No Earnings; Should You Worry?

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Analysis Article • Apr 17

MediPharm Labs Corp. (TSE:LABS) Stocks Shoot Up 27% But Its P/S Still Looks Reasonable

The MediPharm Labs Corp. ( TSE:LABS ) share price has done very well over the last month, posting an excellent gain of...
Analysis Article • Aug 20

Time To Worry? Analysts Just Downgraded Their MediPharm Labs Corp. (TSE:LABS) Outlook

The latest analyst coverage could presage a bad day for MediPharm Labs Corp. ( TSE:LABS ), with the analysts making...
Analysis Article • May 21

Some Analysts Just Cut Their MediPharm Labs Corp. (TSE:LABS) Estimates

One thing we could say about the analysts on MediPharm Labs Corp. ( TSE:LABS ) - they aren't optimistic, having just...
Analysis Article • Apr 06

Things Look Grim For MediPharm Labs Corp. (TSE:LABS) After Today's Downgrade

The latest analyst coverage could presage a bad day for MediPharm Labs Corp. ( TSE:LABS ), with the analysts making...

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as MediPharm Labs has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

TSX:LABS - Analysts future estimates and past financials data (CAD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
3/31/202643-9-3-3N/A
12/31/202545-8-6-6N/A
9/30/202546-8-7-7N/A
6/30/202544-9-8-8N/A
3/31/202543-7-7-6N/A
12/31/202442-11-5-5N/A
9/30/202439-12-3-2N/A
6/30/202438-13-5-5N/A
3/31/202437-14-11-11N/A
12/31/202333-13-13-12N/A
9/30/202330-16-15-14N/A
6/30/202328-20-14-14N/A
3/31/202323-26-14-14N/A
12/31/202222-30-17-16N/A
9/30/202222-46-21-20N/A
6/30/202220-46-18-17N/A
3/31/202221-48-13-13N/A
12/31/202122-55-14-13N/A
9/30/202122-64-17-16N/A
6/30/202122-72-27-26N/A
3/31/202130-63-33-28N/A
12/31/202036-66-45-38N/A
9/30/202062-39-46-29N/A
6/30/2020101-20-67-40N/A
3/31/2020118-15-74-45N/A
12/31/20191292N/A-25N/A
9/30/20191071N/A-27N/A
6/30/201964-4N/A-12N/A
3/31/201932-8N/A-4N/A
12/31/201810-8N/A-11N/A
9/30/2018N/A-6N/A-10N/A
6/30/2018N/A-4N/A-4N/A
3/31/2018N/A-2N/A-3N/A
12/31/2017N/A-1N/A0N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if LABS's forecast earnings growth is above the savings rate (3%).

Earnings vs Market: Insufficient data to determine if LABS's earnings are forecast to grow faster than the Canadian market

High Growth Earnings: Insufficient data to determine if LABS's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if LABS's revenue is forecast to grow faster than the Canadian market.

High Growth Revenue: Insufficient data to determine if LABS's revenue is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if LABS's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/07/06 10:08
End of Day Share Price 2026/07/06 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

MediPharm Labs Corp. is covered by 6 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Aaron GreyAlliance Global Partners
Tamy ChenBMO Capital Markets Equity Research
Kimberly Thompson-HedlinCanaccord Genuity